Assessing the Value of Biosimilars: The Current and Future Impact on Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sandoz Inc., a Novartis Division

Description:
Biologic agents have revolutionized the treatment of many diseases, including breast cancer, lung cancer, non-Hodgkin’s lymphoma, hepatitis, inflammatory bowel disease (IBD), rheumatoid arthritis, and many more. Biosimilars are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers. The development of new biologics may be a big step in effectively treating diseases for which there are currently no cures. At present, there are biosimilars for filgrastim, infliximab, etanercept, adalimumab, trastuzumab, and bevacizumab. The FDA looks at biosimilars as a biological product that is similar to a U.S. licensed biological product not including minor differences in clinically inactive components, as well as having no clinically meaningful differences between the biological product and the reference product in terms of the safety, efficacy and potency of the product. Recent and upcoming patent expirations for some of the most commonly used biologic agents have led to the development of biosimilar products. Evidence suggests that clinicians need to be continually educated about the multiple aspects of biosimilars, including the underlying scientific principles, the development and regulatory pathways, how to use them in clinical practice, as well as educating their patients about their value.

Upon completion of this activity, participants will be able to:

  • Assess the efficacy and safety data for biosimilar products in relation to the data for their reference biological products

  • Analyze the latest advances, available clinical data, and emerging research surrounding biosimilar treatments and their impact on the standard of care

  • Explore the clinical, cost, and regulatory considerations that impact the integration of oncology biosimilar treatments into clinical pathways

  • Discuss how the availability of biosimilars will impact formulary diagnostic criteria and tier placement

  • Evaluate the benefits and challenges of integrating emerging biosimilars into different treatment pathways
     

Faculty: Robert M. Rifkin, MD, FACP
Medical Director, Biosimilars
Associate Chair, US Oncology Hematology Research
The US Oncology Network

Disclosure:

Dr. Rifkin serves on an advisory board for Amgen, Coherus, Mylan, Pfizer and Sandoz. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sandoz Inc., a Novartis Division

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue